Benzinga | Aug 18, 2021 07:03AM EDT

Agios' Rare Anemia Drug Application Under FDA Priority Review

* The FDA has accepted Agios Pharmaceuticals Inc's (NASDAQ:AGIO) marketing application seeking approval for mitapivat for pyruvate kinase (PK) deficiency.

* Under Priority Review designation, the agency's action date is assigned as of February 17, 2022.

* Related: Agios Pharma Files US Application For Mitapivat In PK Deficiency.

* Mitapivat application is under review with the European Medical Agency for the same indication.

* Pyruvate kinase (PK) deficiency is a rare, inherited disease that presents chronic hemolytic anemia, the accelerated destruction of red blood cells.

* Related content: Benzinga's Full FDA Calendar.

* Price Action: AGIO shares closed 2.38% higher at $44.65 on Tuesday.